Sensei Biotherapeutics (NASDAQ:FTH) CEO Buys $55,446.56 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Sensei Biotherapeutics Stock Down 7.3%

Shares of FTH opened at $22.87 on Friday. The firm has a market cap of $30.69 million, a price-to-earnings ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a 1-year low of $6.32 and a 1-year high of $36.76.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on FTH shares. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. HC Wainwright assumed coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 price target for the company. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday. They set an “outperform” rating and a $57.00 price target for the company. Finally, BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.